Navigation Links
Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Date:10/7/2008

and dose response of linaclotide in patients with IBS-C. The primary efficacy endpoint was change from baseline in CSBM frequency. The study evaluated the effects of 75, 150, 300 or 600 ug linaclotide or placebo administered orally once daily to adults meeting modified Rome II criteria for IBS-C. Participants underwent two-week-baseline, 12-week-treatment, and two-week-post-treatment evaluations with daily assessments of bowel habits and symptom severity, and weekly global assessments using an interactive voice response system. During the baseline period patients had to demonstrate <3 CSBM/week and mean daily abdominal pain of at least mild severity. Treatment effects in the intent-to-treat population were estimated using an analysis of covariance and the Cochran-Mantel Haenszel test.

About Linaclotide

Linaclotide is a first-in-class compound currently being evaluated for the treatment of IBS-C, CC, and other gastrointestinal disorders. Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. Linaclotide demonstrated proof of concept in a comprehensive Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linaclotide reduced abdominal pain and relieved constipation-the hallmarks of the condition- throughout the 12-week treatment period. In patients with CC, linaclotide reduced constipation throughout the 4-week study period. Linaclotide was well tolerated at all doses in both Phase 2b studies, with the most common adverse event being diarrhea. A United States patent covering linaclotide composition of matter expires in 2025. In September 2007, Ironwood and Forest Laboratories entered into a 50/50 collaboration to co-develop and co-promote linaclotide in the United States. Ironwood retains exclusive rights to linaclotide outside of North America.
'/>"/>

SOURCE Forest Laboratories, Inc.; Ironwood Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
2. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
3. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
4. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
5. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
6. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
7. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
8. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
9. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
10. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
11. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 For its ... California , Art,s-Way Scientific has earned a ... With competition in over 30 categories, MBI,s contest ... MBI members, which include building manufacturers, dealers, and product ... an excellent example the capability of our team," said ...
(Date:7/31/2014)... LONDON , July 31, 2014 ... for the medical industries, announced today the incorporation of genae UK ... United Kingdom has one of the largest medical device ... in 2012 and it is projected to increase by a CAGR ... billion in 2012, equal to 9.5% of GDP. Despite recessionary pressures, ...
(Date:7/31/2014)... NEW YORK , July 31, 2014 /PRNewswire-USNewswire/ ... of discovering and developing better, faster and affordable ... as Senior Vice President, External Affairs. Mr. ... served as Head of Major Donor Relations for ... Fund). In his role, Mr. Brock will guide ...
Breaking Medicine Technology:Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4genae Opens Offices in London 2TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2
... 15 The U.S. Food and Drug Administration (FDA), ... Justice (USDOJ), today announced that Forest Pharmaceuticals, Inc. entered ... responsibility for criminal actions including distribution of an unapproved ... of an FDA inspection. (Logo:   ...
... 15 New England Biolabs (NEB) has announced ... of $1.22 million to fund the research and ... (Logo: http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b) (Logo: http://www.newscom.com/cgi-bin/prnh/20090921/NE79207LOGO-b) ... developing tools that advance epigenetics research and discovery, ...
Cached Medicine Technology:Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws 2Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws 3New England Biolabs Receives Award to Develop Novel Enzymatic Reagents for Epigenetic Studies 2
(Date:7/31/2014)... A program for anyone looking to ... University of Colorado Anschutz Health and Wellness Center ... camp and transformation program. , “Extreme Weight Loss: ... USA, is an evidenced-based program inspired by the unscripted ... USA. This season, the show has participants spending their ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 Dr. ... closure in front of an enthusiastic audience of international ... Trichophytic Closure improves the appearance of a patient’s ... results of this procedure are minimally detectable in most ... technique improves on the original method of donor wound ...
(Date:7/31/2014)... July 31, 2014 You’re having a wonderful ... have you suddenly developed chills and fever, headache, stiff neck, ... suspect a flu-like illness, it could actually be the first ... risk of developing Lyme is greater than you might think. ... cases occurred in the U.S. annually. But the Centers for ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 According to ... Business Journal , Endo International, one of several manufacturing ... thousands of transvaginal claims for $830 million (in re: ... Litigation (MDL No. 2325). Melinda Helbock, Founder of The ... agrees with the settlement and is pleased to see ...
(Date:7/31/2014)... LDM Global ( http://www.ldmglobal.com ) announces ... is simplified and predictable with fixed fees across the ... leading international provider of legal discovery management services for ... glaringly apparent that both the courts and legal counsel ... the complex pricing structure that plagues the litigation support ...
Breaking Medicine News(10 mins):Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 3Health News:Novel Technique in Wound Closure Delivers More Discreet Results in Hair Transplant Patients 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 3Health News:San Diego Product Liability Firm Provides Commentary on the Latest Developments in Transvaginal Mesh Litigation 2Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2
... Medical Manager and Misys Customers Get Discount to Switch ... ... 2008 -- CollaborateMD, a leading provider of Internet practice management ... industry, announced today an upgrade program for existing users of ...
... Calif., Aug. 13 Watson,Pharmaceuticals, Inc. (NYSE: ... that the United States District Court for the,Southern ... Sodium ER,tablets, the generic version of Naprelan(R), infringes ... action, Elan Corporation Plc v.,Andrx Pharmaceuticals, Inc., was ...
... Things are getting even rosier for,MGM Consumer ... that actress Emmy Rossum has signed on as ... as,Bulma in the upcoming feature film "Dragonball," and ... daughter), "The Phantom of the Opera" (as,Christine) and ...
... donations for breast cancer,research/programs, DETROIT, Aug. 13 ... part to end cancer, as well as honor the ... goal of walking 18,marathons in 18 days -- The ... cancer research and programs at the Barbara Ann Karmanos ...
... Olympics focuses attention on health problems outside the lungs, ... Air pollution has short-term and long-term toxic effects on ... cardiac illness, and even cause death, a new report ... in the Aug. 26 issue of the Journal ...
... Cutting-Edge Patient Safety ... ... with Kahala Nui, a Life Care Retirement Community in Honolulu,Hawai,i, to ... Care Center. Kahala Nui joins a list of,progressive healthcare facilities by ...
Cached Medicine News:Health News:CollaborateMD Offers Upgrade Program to Competitors' Users 2Health News:Watson Announces District Court Ruling in Naproxen Sodium Patent Suit 2Health News:Watson Announces District Court Ruling in Naproxen Sodium Patent Suit 3Health News:Actress Emmy Rossum to Act as Official Spokesperson of PiNKiTUDE, New Cause Marketing Initiative Inspired by MGM's Pink Panther, Benefits Susan G. Komen for the Cure(R) 2Health News:Actress Emmy Rossum to Act as Official Spokesperson of PiNKiTUDE, New Cause Marketing Initiative Inspired by MGM's Pink Panther, Benefits Susan G. Komen for the Cure(R) 3Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 2Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 3Health News:Air Pollution Can Damage Heart, Blood Vessels, Too 2Health News:Hoana Medical, Inc. Partners With Kahala Nui to Improve Patient Safety 2Health News:Hoana Medical, Inc. Partners With Kahala Nui to Improve Patient Safety 3Health News:Hoana Medical, Inc. Partners With Kahala Nui to Improve Patient Safety 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: